13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FAILURES IN MASSACHUSETTS CHILDREN, 2010/2017 (ID 492)
- Inci Yildirim, United States of America
- Inci Yildirim, United States of America
- Hillary Johnson,
- Stephen I. Pelton, United States of America
Abstract
Background
Despite high vaccine coverage rates in children and efficacy of pneumococcal conjugate vaccines, invasive pneumococcal disease (IPD) episodes due to serotypes included in the vaccine following completion of the recommended course of immunisation [i.e. vaccine failure (VF)] have been reported.
Methods
Cases of IPD in children <18 years of age were detected through an enhanced surveillance system. Parents/physicians/providers are interviewed for confirmation of demographic and clinical data. All Streptococcus pneumoniae from sterile body sites are submitted to Department of Public Health and serotyped by Quellung reaction.
Results
Out of 307 IPD cases identified during 2010/2017 following implementation of PCV13, 101 (32.9%) were due to PCV13 serotypes and 27 (8.8%) were among children who completed age-recommended immunization schedule (Table). Median age was 26 months, 21 (67.7%) were male and 6 (22.2%) of cases had >1 comorbidity. Serotype 19A (n=13, 48.2%) and 3 (n=11, 40.7%) were responsible for majority of VF cases. Mortality rate among VF cases was 11.1%.
Conclusions
PCVs are highly effective, but sustaining high vaccine coverage, ongoing surveillance and understanding the mechanisms involved in VF cases is essential